{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:48:16Z","timestamp":1781920096448,"version":"3.54.5"},"reference-count":117,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.intimp.2015.03.020","type":"journal-article","created":{"date-parts":[[2015,4,5]],"date-time":"2015-04-05T22:16:49Z","timestamp":1428272209000},"page":"213-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Biologic therapy in ANCA-negative vasculitis"],"prefix":"10.1016","volume":"27","author":[{"given":"Javier","family":"Loricera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinitario","family":"Pina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Carmen","family":"Gonz\u00e1lez-Vela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4754-0277","authenticated-orcid":false,"given":"Miguel A.","family":"Gonz\u00e1lez-Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2015.03.020_bb0005","doi-asserted-by":"crossref","first-page":"345","DOI":"10.7326\/0003-4819-129-5-199809010-00001","article-title":"Limitations of the 1990 American College of rheumatology classification criteria in the diagnosis of vasculitis","volume":"129","author":"Rao","year":"1998","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.intimp.2015.03.020_bb0010","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of systemic vasculitides. Proposal of an international consensus conference","volume":"37","author":"Jennette","year":"1994","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.intimp.2015.03.020_bb0020","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/MD.0b013e31821c4fad","article-title":"Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain","volume":"90","author":"Martinez-Lado","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.intimp.2015.03.020_bb0025","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J","article-title":"An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients","volume":"43","author":"Reinhold-Keller","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0030","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.45.2.136","article-title":"Azathioprine in giant cell arteritis\/polymyalgia rheumatica: a double-blind study","volume":"45","author":"De Silva","year":"1986","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2015.03.020_bb0035","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A multicenter, randomized, doubleblind, placebo-controlled trial of adjuvant MTX treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0040","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant cell arteritis with MTX and prednisone: a randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.intimp.2015.03.020_bb0045","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive MTX for treatment of giant cell arteritis: an individual patient data meta-analysis","volume":"56","author":"Mahr","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0050","first-page":"495","article-title":"A prospective, double-blind, randomized, placebo controlled trial of MTX in the treatment of giant cell arteritis (GCA)","volume":"19","author":"Spiera","year":"2001","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0055","first-page":"S43","article-title":"Cyclophosphamide for large vessel vasculitis: assessment of response by PET\/CT","volume":"29","author":"Henes","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0060","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/art.22404","article-title":"Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients","volume":"56","author":"Maksimowicz-McKinnon","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0065","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S0167-5273(96)88780-8","article-title":"Current status of Takayasu arteritis in India","volume":"54","author":"Jain","year":"1996","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0070","first-page":"S9","article-title":"Takayasu arteritis: clinical features in 110 Mexican Mestizo patients and cardiovascular impact on survival and prognosis","volume":"26","author":"Soto","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0075","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.1780370420","article-title":"Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate","volume":"37","author":"Hoffman","year":"1994","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0080","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7326\/0003-4819-130-5-199903020-00013","article-title":"Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases","volume":"130","author":"Daina","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.intimp.2015.03.020_bb0085","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMra011913","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"347","author":"Salvarani","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2015.03.020_bb0090","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/art.24459","article-title":"Epidemiology of giant cell arteritis and polymyalgia rheumatica","volume":"61","author":"Gonz\u00e1lez-Gay","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0095","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00005792-200009000-00001","article-title":"Visual manifestations of giant cell arteritis: trends and clinical spectrum in 161 patients","volume":"79","author":"Gonz\u00e1lez-Gay","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.intimp.2015.03.020_bb0100","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.md.0000145369.25558.b5","article-title":"Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis","volume":"83","author":"Gonzalez-Gay","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.intimp.2015.03.020_bb0105","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0889-857X(05)70232-5","article-title":"Epidemiology of the vasculitides","volume":"27","author":"Gonzalez-Gay","year":"2001","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.intimp.2015.03.020_bb0110","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1002\/art.11353","article-title":"Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and\/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50years","volume":"48","author":"Nuenninghoff","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0115","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/01.md.0000145366.40805.f8","article-title":"Aortic aneurysm and dissection in biopsy-proven giant cell arteritis patients from Northwest Spain. A population-based study","volume":"83","author":"Gonz\u00e1lez-Gay","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.intimp.2015.03.020_bb0120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F","article-title":"Disease pattern in cranial and large-vessel giant cell arteritis","volume":"42","author":"Brack","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0125","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/art.1780371020","article-title":"Thoracic aortic aneurysm and rupture in giant cell arteritis. A descriptive study of 41 cases","volume":"37","author":"Evans","year":"1994","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0130","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/rheumatology\/ker329","article-title":"Large-vessel involvement in recent-onset giant cell arteritis: a case\u2013control colour-Doppler sonography study","volume":"51","author":"Ghinoi","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2015.03.020_bb0135","doi-asserted-by":"crossref","first-page":"806","DOI":"10.7326\/0003-4819-83-6-806","article-title":"Large artery involvement in giant cell (temporal) arteritis","volume":"83","author":"Klein","year":"1975","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.intimp.2015.03.020_bb0140","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0049-0172(95)80010-7","article-title":"Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathologic documentation","volume":"24","author":"Lie","year":"1995","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0145","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/rheumatology\/keh513","article-title":"Giant cell arteritis and polymyalgia rheumatica: usefulness of vascular magnetic resonance imaging studies in the diagnosis of aortitis","volume":"44","author":"Narv\u00e1ez","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2015.03.020_bb0150","article-title":"Non-infectious aortitis: a report of 32 cases from a single tertiary centre in a 4-year period and literature review","volume":"33","author":"Loricera","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0155","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s11926-010-0135-9","article-title":"Giant cell arteritis: epidemiology, diagnosis, and management","volume":"12","author":"Gonzalez-Gay","year":"2010","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.intimp.2015.03.020_bb0160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/BOR.0b013e32831d28b3","article-title":"Advances in the use of biologic agents for the treatment of systemic vasculitis","volume":"21","author":"Chung","year":"2009","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0165","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1002\/1529-0131(200112)44:12<2933::AID-ART482>3.0.CO;2-Y","article-title":"Treatment of long-standing active giant cell arteritis with infliximab: report of four cases","volume":"44","author":"Cantini","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0170","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab-GCA Study Group. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.intimp.2015.03.020_bb0175","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/ard.2007.082115","article-title":"A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects","volume":"67","author":"Mart\u00ednez-Taboada","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2015.03.020_bb0180","article-title":"Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial","author":"Seror","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2015.03.020_bb0185","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1136\/annrheumdis-2013-204462","article-title":"Is TNF-\u03b1 really involved in giant cell arteritis pathogenesis?","volume":"73","author":"Samson","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2015.03.020_bb0190","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1002\/art.34647","article-title":"Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatic pathogenesis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0195","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.34477","article-title":"Inhibition of interleukin-6 function corrects Th17\/Treg cell imbalance in patients with rheumatoid arthritis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0200","first-page":"S79","article-title":"Tocilizumab in refractory aortitis: study on 16 patients and literature review","volume":"32","author":"Loricera","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0205","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/rheumatology\/ker296","article-title":"Tocilizumab: a novel therapy for patients with large-vessel vasculitis","volume":"51","author":"Salvarani","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.intimp.2015.03.020_bb0210","first-page":"w13156","article-title":"Rapid induction of remission in large vessel vasculitis by IL-6 blockade: a case series","volume":"141","author":"Seitz","year":"2011","journal-title":"Swiss Med. Wkly."},{"key":"10.1016\/j.intimp.2015.03.020_bb0215","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.3899\/jrheum.110496","article-title":"Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis","volume":"38","author":"Sciascia","year":"2011","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0220","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1136\/ard.2010.149351","article-title":"Antiinterleukin 6 receptor therapy as rescue treatment for giant cell arteritis","volume":"70","author":"Beyer","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2015.03.020_bb0225","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/acr.21750","article-title":"Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatic","volume":"64","author":"Unizony","year":"2012","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.intimp.2015.03.020_bb0230","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.04.2011.4135","article-title":"Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement","author":"Christidis","year":"2011","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.intimp.2015.03.020_bb0235","first-page":"S59","article-title":"Tocilizumab in glucocorticoid-na\u00efve large-vessel vasculitis. Case report","volume":"31","author":"Pazzola","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0240","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jbspin.2011.11.008","article-title":"Efficacy of tocilizumab in refractory giant cell arteritis","volume":"79","author":"Vinit","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.intimp.2015.03.020_bb0245","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s10067-012-2007-3","article-title":"Ultrasonographic resolution of the vessel wall oedema with modest clinical improvement in a large-vessel vasculitis patient treated with tocilizumab","volume":"31","author":"Besada","year":"2012","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0250","first-page":"912562","article-title":"Design of the tocilizumab in giant cell arteritis trial","volume":"2013","author":"Unizony","year":"2013","journal-title":"Int. J. Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0255","first-page":"757","article-title":"Takayasu arteritis: diverse aspects of a rare disease","volume":"14","author":"Balbir-Gurman","year":"2012","journal-title":"Isr. Med. Assoc. J."},{"key":"10.1016\/j.intimp.2015.03.020_bb0260","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/jcp.55.7.481","article-title":"Takayasu arteritis: a review","volume":"55","author":"Johnston","year":"2002","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0265","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00467-009-1312-9","article-title":"Large vessel vasculitis","volume":"25","author":"Gulati","year":"2010","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0270","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00005792-198503000-00002","article-title":"Takayasu arteritis: a study of 32 North American patients","volume":"64","author":"Hall","year":"1985","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.intimp.2015.03.020_bb0275","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0889-857X(21)00371-9","article-title":"Treatment of resistant Takayasu's arteritis","volume":"21","author":"Hoffman","year":"1995","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.intimp.2015.03.020_bb0280","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1002\/art.20300","article-title":"Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis","volume":"50","author":"Hoffman","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0285","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/ard.2008.093260","article-title":"Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up","volume":"67","author":"Molloy","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2015.03.020_bb0290","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/rheumatology\/keh661","article-title":"Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent?","volume":"44","author":"Della Rossa","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2015.03.020_bb0295","first-page":"922","article-title":"Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab","volume":"30","author":"Quartuccio","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0300","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/acr.21636","article-title":"Tumor necrosis factor inhibitors in patients with Takayasu arteritis experience from a referral center with long-term follow-up","volume":"64","author":"Schmidt","year":"2012","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.intimp.2015.03.020_bb0305","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.autrev.2011.11.025","article-title":"Anti TNF-alpha in refractory Takayasu's arteritis: cases series and review of the literature","volume":"11","author":"Comarmond","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2015.03.020_bb0310","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s12016-007-8028-z","article-title":"Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?","volume":"34","author":"Galarza","year":"2008","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0315","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/ard.2011.153007","article-title":"Takayasu arteritis is characterized by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab","volume":"71","author":"Hoyer","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2015.03.020_bb0320","first-page":"406963","article-title":"Remission achieved in refractory advanced Takayasu arteritis using rituximab","volume":"2012","author":"Ernst","year":"2012","journal-title":"Case Rep. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0325","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/art.23373","article-title":"Successful treatment of a patient with Takayasu arteritis using a humanized antiinterleukin-6 receptor antibody","volume":"58","author":"Nishimoto","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0330","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.autrev.2013.06.019","article-title":"Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review","volume":"12","author":"Abisror","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2015.03.020_bb0335","first-page":"S90","article-title":"Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-alpha blockers","volume":"30","author":"Salvarani","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0340","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3899\/jrheum.130536","article-title":"Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center","volume":"40","author":"Tombetti","year":"2013","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0345","first-page":"S11","article-title":"Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-\u03b1 and IL-6 receptor targeted therapies in refractory Takayasu arteritis","volume":"32","author":"Youngstein","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0350","first-page":"S98","article-title":"One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab","volume":"30","author":"Bredemeier","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0355","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/rheumatology\/ket107","article-title":"Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis","volume":"52","author":"Xenitidis","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2015.03.020_bb0360","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/ard.53.5.334","article-title":"Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges","volume":"53","author":"Guillevin","year":"1994","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2015.03.020_bb0365","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/art.20401","article-title":"Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa","volume":"5","author":"Guillevin","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0370","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2015.03.020_bb0375","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2015.03.020_bb0380","series-title":"Up to Date","article-title":"Treatment and prognosis of polyarteritis nodosa","author":"Merkel","year":"2014"},{"key":"10.1016\/j.intimp.2015.03.020_bb0385","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1097\/00006454-199812000-00009","article-title":"Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US\/Canadian Kawasaki Syndrome Study Group.","volume":"17","author":"Burns","year":"1998","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.intimp.2015.03.020_bb0390","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0022-3476(05)80343-9","article-title":"Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor alpha among patients with Kawasaki disease","volume":"12","author":"Lin","year":"1992","journal-title":"J. Pediatr."},{"key":"10.1016\/j.intimp.2015.03.020_bb0395","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0090-1229(90)90166-N","article-title":"Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions","volume":"56","author":"Matsubara","year":"1990","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0400","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJM198608073150601","article-title":"The treatment of Kawasaki syndrome with intravenous gamma globulin","volume":"315","author":"Newburger","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2015.03.020_bb0405","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1056\/NEJM199106063242305","article-title":"A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome","volume":"324","author":"Newburger","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2015.03.020_bb0410","first-page":"542","article-title":"Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease","volume":"43","author":"Burns","year":"2008","journal-title":"J. Pediatr."},{"key":"10.1016\/j.intimp.2015.03.020_bb0415","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(13)62298-9","article-title":"Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial","volume":"383","author":"Tremoulet","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2015.03.020_bb0420","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jpeds.2010.10.012","article-title":"Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study","volume":"158","author":"Son","year":"2011","journal-title":"J. Pediatr."},{"key":"10.1016\/j.intimp.2015.03.020_bb0425","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4103\/0974-2069.126578","article-title":"Infliximab as rescue therapy in refractory Kawasaki disease","volume":"7","author":"Rodr\u00edguez-Gonz\u00e1lez","year":"2014","journal-title":"Ann. Pediatr. Cardiol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0430","first-page":"543141","article-title":"Etanercept suppresses arteritis in a murine model of Kawasaki disease: a comparative study involving different biological agents","volume":"2013","author":"Ohashi","year":"2013","journal-title":"Int. J. Vasc. Med."},{"key":"10.1016\/j.intimp.2015.03.020_bb0435","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/BF02190688","article-title":"Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease","volume":"153","author":"Furukawa","year":"1994","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.intimp.2015.03.020_bb0440","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/rheumatology\/keu295","article-title":"Single-organ cutaneous small-vessel vasculitis according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides: a study of 60 patients from a series of 766 cutaneous vasculitis cases","volume":"54","author":"Loricera","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2015.03.020_bb0445","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000350559","article-title":"Rituximab therapy for severe cutaneous leukocytoclastic angiitis refractory to corticosteroids, cellcept and cyclophosphamide","volume":"5","author":"El-Reshaid","year":"2013","journal-title":"Case Rep. Dermatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0450","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/MD.0000000000000013","article-title":"Urticarial vasculitis in northern Spain: clinical study of 21 cases","volume":"93","author":"Loricera","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.intimp.2015.03.020_bb0455","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-2133.2008.08990.x","article-title":"Refractory urticarial vasculitis responsive to anti-B-cell therapy","volume":"160","author":"Mukhtyar","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0460","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/03009740600938647","article-title":"Non-complementaemic urticarial vasculitis: successful treatment with the IL-1 receptor antagonist, anakinra","volume":"36","author":"Botsios","year":"2007","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0465","first-page":"354","article-title":"Successful use of anakinra to treat refractory Schnitzler's syndrome","volume":"26","author":"Dybowski","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0470","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/039463201002300226","article-title":"Successful treatment of Schnitzler's syndrome with anakinra after failure of rituximab trial","volume":"23","author":"Cascavilla","year":"2010","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0475","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jaci.2013.04.008","article-title":"Efficacy and safety of canakinumab in urticarial vasculitis: an open-label study","volume":"132","author":"Krause","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0480","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/ndt\/14.6.1558","article-title":"Successful treatment of HCV-associated cryoglobulinaemic glomerulonephritis with a combination of interferon-alpha and ribavirin","volume":"14","author":"Misiani","year":"1999","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.intimp.2015.03.020_bb0485","first-page":"2172","article-title":"Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha","volume":"27","author":"Zuckerman","year":"2000","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0490","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jhep.2004.10.031","article-title":"Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study","volume":"42","author":"Mazzaro","year":"2005","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0495","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/art.20958","article-title":"PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis","volume":"52","author":"Cacoub","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0500","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/BOR.0b013e32835b15f7","article-title":"Cryoglobulinemic vasculitis: an update","volume":"25","author":"Terrier","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0505","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1182\/blood-2002-09-2856","article-title":"Efficacy and safety of rituximab in type II mixed cryoglobulinemia","volume":"101","author":"Zaja","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.03.020_bb0510","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2002-10-3162","article-title":"Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20","volume":"101","author":"Sansonno","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.03.020_bb0515","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood-2009-10-248518","article-title":"Rituximab plus Peg-interferon-alpha\/ribavirin compared with Peg-interferon a\/ribavirin in hepatitis C-related mixed cryoglobulinemia","volume":"116","author":"Saadoun","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.03.020_bb0520","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1093\/ndt\/gfh469","article-title":"Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis","volume":"19","author":"Roccatello","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.intimp.2015.03.020_bb0525","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1136\/ard.2007.081653","article-title":"Rituximab combined with Peginterferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis","volume":"67","author":"Saadoun","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2015.03.020_bb0530","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1002\/art.24703","article-title":"Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term follow-up study of thirty-two patients","volume":"60","author":"Terrier","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0535","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.34331","article-title":"A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis","volume":"64","author":"De Vita","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0540","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/art.34322","article-title":"A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis","volume":"64","author":"Sneller","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0545","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2009-10-245878","article-title":"Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study","volume":"116","author":"Dammacco","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.03.020_bb0550","doi-asserted-by":"crossref","first-page":"5996","DOI":"10.1182\/blood-2011-12-396028","article-title":"Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey","volume":"119","author":"Terrier","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.03.020_bb0555","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/MD.0000000000000019","article-title":"Henoch\u2013Sch\u00f6nlein purpura in northern Spain: clinical spectrum of the disease in 417 patients from a single center","volume":"93","author":"Calvo-R\u00edo","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.intimp.2015.03.020_bb0560","first-page":"S34","article-title":"Revisiting clinical differences between hypersensitivity vasculitis and Henoch\u2013Sch\u00f6nlein purpura in adults from a defined population","volume":"32","author":"Calvo-R\u00edo","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.020_bb0565","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/art.1780400513","article-title":"Henoch\u2013Sch\u00f6nlein purpura in adulthood and childhood: two different expressions of the same syndrome","volume":"40","author":"Blanco","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.020_bb0570","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jpeds.2008.12.049","article-title":"Rituximab therapy for severe refractory chronic Henoch\u2013Sch\u00f6nlein purpura","volume":"155","author":"Donnithorne","year":"2009","journal-title":"J. Pediatr."},{"key":"10.1016\/j.intimp.2015.03.020_bb0575","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1093\/ndt\/gfr137","article-title":"Successful outcome using rituximab as the only immunomodulation in Henoch\u2013Schonlein purpura: case report","volume":"26","author":"Pillebout","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.intimp.2015.03.020_bb0580","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1755-6686.2013.12007.x","article-title":"Refractory Henoch\u2013Sch\u00f6nlein purpura: atypical aetiology and management","volume":"39","author":"El-Husseini","year":"2013","journal-title":"J. Ren. Care"},{"key":"10.1016\/j.intimp.2015.03.020_bb0585","doi-asserted-by":"crossref","first-page":"619218","DOI":"10.1155\/2014\/619218","article-title":"Successful outcome of a corticodependent Henoch\u2013Sch\u00f6nlein purpura adult with rituximab","volume":"2014","author":"Pindi Sala","year":"2014","journal-title":"Case Rep. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576915001228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576915001228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T06:26:18Z","timestamp":1717827978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576915001228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":117,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1567576915001228"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2015.03.020","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic therapy in ANCA-negative vasculitis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2015.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}